Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...

ConferenceHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CESTThe issuer is solely responsible for the content of this ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...